UA108346C2 - METHOD OF MODULATION OF ANTAGONISTIC ACTIVITY OF MONOCLONAL ANTIBODY - Google Patents

METHOD OF MODULATION OF ANTAGONISTIC ACTIVITY OF MONOCLONAL ANTIBODY

Info

Publication number
UA108346C2
UA108346C2 UAA201108283A UAA201108283A UA108346C2 UA 108346 C2 UA108346 C2 UA 108346C2 UA A201108283 A UAA201108283 A UA A201108283A UA A201108283 A UAA201108283 A UA A201108283A UA 108346 C2 UA108346 C2 UA 108346C2
Authority
UA
Ukraine
Prior art keywords
seq
hinge region
amino acid
antagonistic activity
modulation
Prior art date
Application number
UAA201108283A
Other languages
Russian (ru)
Ukrainian (uk)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2009/066205 external-priority patent/WO2010063746A1/en
Publication of UA108346C2 publication Critical patent/UA108346C2/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Abstract

Винахід стосується способу підвищення антагоністичної активності моноклонального химерного або гуманізованого антитіла, що включає константну область IgG1 людини, та націленого проти специфічної молекули-мішені, або його двовалентного функціонального фрагмента, при цьому зазначене антитіло здатне інгібувати одну чи декілька біологічних активностей зазначеної молекули-мішені, де зазначений спосіб включає етап реконфігурації шарнірної області, що полягає у модифікації амінокислотної послідовності зазначеної шарнірної області шляхом видалення, додання або заміни щонайменше однієї амінокислоти, та де зазначена реконфігурована шарнірна область, одержана шляхом модифікації її амінокислотної послідовності, утворює шарнірну область, яка має послідовність вибрану з групи, що складається з послідовностей SEQ ID № 2, SEQ ID № 4, SEQ ID № 6, SEQ ID № 23- SEQ ID № 26, SEQ ID № 36 та SEQ ID № 42 - SEQ ID № 49.The invention relates to a method of increasing the antagonistic activity of a monoclonal chimeric or humanized antibody comprising a constant region of human IgG1 and targeted against a specific target molecule, or its divalent functional fragment, wherein said antibody is capable of inhibiting one or more biological or multifaceted activities. the method includes the step of reconfiguring the hinge region, which is to modify the amino acid sequence of the specified hinge region by removing, adding or replacing at least one amino acid, and wherein said reconfigured hinge region, obtained by modifying its amino acid sequence, forms a hinge region having a sequence selected from the group consisting of SEQ ID No. 2, SEQ ID No. 4, SEQ ID No. 4 # 6, SEQ ID # 23- SEQ ID # 26, SEQ ID # 36, and SEQ ID # 42 - SEQ ID # 49.

UAA201108283A 2008-12-02 2009-02-12 METHOD OF MODULATION OF ANTAGONISTIC ACTIVITY OF MONOCLONAL ANTIBODY UA108346C2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/IB2008/055664 WO2010064090A1 (en) 2008-12-02 2008-12-02 Process for the modulation of the antagonistic activity of a monoclonal antibody
PCT/EP2009/066205 WO2010063746A1 (en) 2008-12-02 2009-12-02 Process for the modulation of the antagonistic activity of a monoclonal antibody

Publications (1)

Publication Number Publication Date
UA108346C2 true UA108346C2 (en) 2015-04-27

Family

ID=40875011

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA201108283A UA108346C2 (en) 2008-12-02 2009-02-12 METHOD OF MODULATION OF ANTAGONISTIC ACTIVITY OF MONOCLONAL ANTIBODY

Country Status (2)

Country Link
UA (1) UA108346C2 (en)
WO (1) WO2010064090A1 (en)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006106905A1 (en) 2005-03-31 2006-10-12 Chugai Seiyaku Kabushiki Kaisha Process for production of polypeptide by regulation of assembly
US9670269B2 (en) 2006-03-31 2017-06-06 Chugai Seiyaku Kabushiki Kaisha Methods of modifying antibodies for purification of bispecific antibodies
ES2568436T3 (en) 2006-03-31 2016-04-29 Chugai Seiyaku Kabushiki Kaisha Procedure to control the blood pharmacokinetics of antibodies
SG10201605394SA (en) 2007-09-26 2016-08-30 Chugai Pharmaceutical Co Ltd Modified Antibody Constant Region
EP3689912A1 (en) 2007-09-26 2020-08-05 Chugai Seiyaku Kabushiki Kaisha Method of modifying isoelectric point of antibody via amino acid substitution in cdr
US9228017B2 (en) 2009-03-19 2016-01-05 Chugai Seiyaku Kabushiki Kaisha Antibody constant region variant
JP5787446B2 (en) 2009-03-19 2015-09-30 中外製薬株式会社 Antibody constant region variants
EP2481752B1 (en) * 2009-09-24 2016-11-09 Chugai Seiyaku Kabushiki Kaisha Modified antibody constant regions
JP5889181B2 (en) 2010-03-04 2016-03-22 中外製薬株式会社 Antibody constant region variants
AU2011226103C1 (en) 2010-03-10 2016-04-28 Genmab A/S Monoclonal antibodies against c-Met
MX2014002289A (en) 2011-08-26 2015-03-20 Merrimack Pharmaceuticals Inc Tandem fc bispecific antibodies.
US9931400B2 (en) 2012-09-12 2018-04-03 Samsung Electronics Co., Ltd. Method of combination therapy for prevention or treatment of c-Met or angiogenesis factor induced diseases
KR20150143458A (en) 2013-03-06 2015-12-23 메리맥 파마슈티컬즈, 인크. ANTI-C-MET Tandem Fc Bispecific Antibodies
KR102441231B1 (en) 2013-09-27 2022-09-06 추가이 세이야쿠 가부시키가이샤 Method for producing polypeptide heteromultimer
US9717715B2 (en) 2013-11-15 2017-08-01 Samsung Electronics Co., Ltd. Method of combination therapy using an anti-C-Met antibody
EP3279216A4 (en) 2015-04-01 2019-06-19 Chugai Seiyaku Kabushiki Kaisha Method for producing polypeptide hetero-oligomer
AU2016381992B2 (en) 2015-12-28 2024-01-04 Chugai Seiyaku Kabushiki Kaisha Method for promoting efficiency of purification of Fc region-containing polypeptide
TW201825515A (en) 2017-01-04 2018-07-16 美商伊繆諾金公司 Met antibodies and immunoconjugates and uses thereof
WO2020014306A1 (en) 2018-07-10 2020-01-16 Immunogen, Inc. Met antibodies and immunoconjugates and uses thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2004309275B2 (en) * 2003-12-25 2010-12-23 Kyowa Kirin Co., Ltd. Mutants of anti-CD40 antibody
JP5142998B2 (en) * 2005-07-18 2013-02-13 アムジエン・インコーポレーテツド Human anti-B7RP1 neutralizing antibody
US8652469B2 (en) * 2005-07-28 2014-02-18 Novartis Ag M-CSF-specific monoclonal antibody and uses thereof
EP2004693B1 (en) * 2006-03-30 2012-06-06 Novartis AG Compositions and methods of use for antibodies of c-met

Also Published As

Publication number Publication date
WO2010064090A1 (en) 2010-06-10

Similar Documents

Publication Publication Date Title
UA108346C2 (en) METHOD OF MODULATION OF ANTAGONISTIC ACTIVITY OF MONOCLONAL ANTIBODY
TN2011000253A1 (en) Process for the modulation of the antagonistic activity of a monoclonal antibody
NZ591471A (en) Antibodies to ccr2
MX2009001110A (en) Anti-il-6 monoclonal antibodies and uses thereof.
PH12014501872A1 (en) P-cadherin antibodies
NZ584838A (en) Novel antibodies which bind alpha5beta1 (fibronectin receptor) and uses thereof
WO2008124083A3 (en) Aurora kinase modulators and method of use
TW200724548A (en) Antibodies to myostatin
RU2015147300A (en) HUMANIZED ANTIBODIES TO CXCR5, THEIR DERIVATIVES AND THEIR APPLICATION
WO2003100033A3 (en) ANTI-αvβ6 ANTIBODIES
GEP20135917B (en) Stabilized polypeptide compositions
NO20082167L (en) Anti-Myostatin Antibodies
CY1112953T1 (en) USE OF ANTI-CD100 ANTIBODIES
MX2009004532A (en) Compositions and methods for binding sphingosine-1-phosphate.
EA200970515A1 (en) MODIFIED SOLUBLE FUSED DESIGNS OF FGF AND Fc RECEPTOR WITH IMPROVED BIOLOGICAL ACTIVITY
IN2010KN00318A (en)
NZ598770A (en) Monoclonal antibodies
WO2008112003A3 (en) Targeted binding agents directed to pdgfr-alpha and uses thereof
WO2012018767A3 (en) Antibodies directed against il-17
EA200901067A1 (en) USE OF SEMAFORIN 6A AS A MIELINIZATION PROMOTER AND DIFFERENTIATION OF OLIGODENDROCYTES
WO2010072740A3 (en) TARGETED BINDING AGENTS DIRECTED TO α5β1 AND USES THEREOF
WO2006132739A3 (en) Novel chemical compounds
NZ774126A (en) Spd-1 variant - fc fusion proteins
ES2570182T3 (en) Prevention and treatment of synucleinopathic and amyloidogenic disease
DK2229946T3 (en) Use of growth-stimulating protein KIAA1524